Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension

American Journal of Ophthalmology

Volumn 160, Issue 2, 2015, Pages 266-274.e1

  Peace, James H ^a   Ahlberg, Peter ^b   Wagner, Mathias ^c   Lim, John M ^d   Wirta, David ^e   Branch, James D ^f  

^a United Medical Research   (United States)

^b FALUN HOSPITAL   (Sweden)

^c Grossräeschen Eye Clinic   (Germany)

^d Houston Eye Associates   (United States)

^e Eye Research Foundation   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; POLIDRONIUM CHLORIDE; TRAVOPROST; ANTIHYPERTENSIVE AGENT; BENZALKONIUM; CLOPROSTENOL; EYE DROPS; POLYMER; PRESERVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRY EYE; EUROPE; EYE IRRITATION; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FOLLOW UP; GLAUCOMA, OPEN-ANGLE; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CLOPROSTENOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; POLYMERS; PRESERVATIVES, PHARMACEUTICAL; RETROSPECTIVE STUDIES; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 84937518894     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2015.04.041     Document Type: Article

References (22)

1. H.A. Quigley Glaucoma: macrocosm to microcosm the Friedenwald lecture Invest Ophthalmol Vis Sci 46 8 2005 2662 2670
2. S. Resnikoff, D. Pascolini, D. Etya'ale, and et al. Global data on visual impairment in the year 2002 Bull World Health Organ 82 11 2004 844 851
3. H.A. Quigley, and A.T. Broman The number of people with glaucoma worldwide in 2010 and 2020 Br J Ophthalmol 90 3 2006 262 267
4. P.C. Maier, J. Funk, G. Schwarzer, G. Antes, and Y.T. Falck-Ytter Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials BMJ 331 7509 2005 134
5. C.A. Webers, H.J. Beckers, R.M. Nuijts, and J.S. Schouten Pharmacological management of primary open-angle glaucoma: second-line options and beyond Drugs Aging 25 9 2008 729 759
6. American Academy of Ophthalmology Glaucoma Panel Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma 2010 American Academy of Ophthalmology San Francisco, CA
7. European Glaucoma Society Terminology and Guidelines for Glaucoma 3rd ed. 2008 Dogma S.r.l Savona, Italy
8. F. Aptel, M. Cucherat, and P. Denis Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials J Glaucoma 17 8 2008 667 673
9. F. Aptel, M. Cucherat, and P. Denis Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials Eur J Ophthalmol 22 1 2012 5 18
10. D.C. Broadway, I. Grierson, C. O'Brien, and R.A. Hitchings Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile Arch Ophthalmol 112 11 1994 1437 1445
11. R.J. Noecker, L.A. Herrygers, and R. Anwaruddin Corneal and conjunctival changes caused by commonly used glaucoma medications Cornea 23 5 2004 490 496
12. Y. Goto, N. Ibaraki, and K. Miyake Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol Arch Ophthalmol 121 6 2003 835 839
13. T. Mundorf, K.A. Wilcox, G.W. Ousler 3rd, D. Welch, and M.B. Abelson Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes Adv Ther 20 6 2003 329 336
14. P.J. Pisella, P. Pouliquen, and C. Baudouin Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication Br J Ophthalmol 86 4 2002 418 423
15. S. Gandolfi, T. Paredes, I. Goldberg, and et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma Eur J Ophthalmol 22 1 2012 34 44
16. L.B. Cantor, J. Hoop, L. Morgan, D. Wudunn, and Y. Catoira Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension Br J Ophthalmol 90 11 2006 1370 1373
17. L.B. Cantor, D. WuDunn, A. Cortes, J. Hoop, and S. Knotts Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension Surv Ophthalmol 49 Suppl 1 2004 S12 18
18. P.A. Netland, T. Landry, E.K. Sullivan, and et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension Am J Ophthalmol 132 4 2001 472 484
19. R.L. Fellman, E.K. Sullivan, M. Ratliff, and et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial Ophthalmology 109 5 2002 998 1008
20. M. Aihara, H. Oshima, and M. Araie E.XTraKT Study Group. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface - a multicentre randomized single-masked study Acta Ophthalmol 91 1 2013 e7 14
21. M.J. Miyashiro, S.C. Lo, J.A. Stewart, and W.C. Stewart Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients Clin Ophthalmol 4 2010 1355 1359
22. J.C. Henry, J.H. Peace, J.A. Stewart, and W.C. Stewart Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy Clin Ophthalmol 2 3 2008 613 621